DENI CAPPAR Stock

DNQAF

KYG6256B1068

Market Closed - OTC Markets Other stock markets 15:53:05 2026-07-24 EDT			5-day change	1st Jan Change
0.6800 ^USD	+4.62%		-5.56%	-94.36%

04-19	Denali Capital Acquisition Corp. cancelled the transaction announced on August 20, 2025	CI
25-09-21	Semnur Pharmaceuticals, Inc. completed the acquisition of Denali Capital Acquisition Corp. from a group of shareholders in a reverse merger transaction.	CI

Denali Capital Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It has not selected any potential business combination target or initiated any substantive discussions, directly or indirectly, with any potential business combination prospects. The Company intends to identify a prospective target business will not be limited to a particular industry or geographic region. The Company intends to focus on identifying business within the technology, hospitality, or consumer services sector. The Company neither engaged in any operations nor generated any revenues.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	US$0.6800	+4.62%	30,530
26-07-23	US$0.6500	-12.16%	1,937
26-07-22	US$0.7400	+15.59%	8,358
26-07-21	US$0.6402	-20.96%	7,383
26-07-20	US$0.8100	+12.50%	6,887

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Market Cap	31.08M 27.29M 25.38M 23.29M 43.76M 2.99B 44.44M 301M 118M 1.47B 117M 114M 5.09B	P/E 2023	161x	P/E 2024	-376x
Enterprise Value	33.83M 29.71M 27.63M 25.36M 47.65M 3.26B 48.38M 328M 128M 1.6B 127M 124M 5.54B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

04-19	Denali Capital Acquisition Corp. cancelled the transaction announced on August 20, 2025	CI
25-09-21	Semnur Pharmaceuticals, Inc. completed the acquisition of Denali Capital Acquisition Corp. from a group of shareholders in a reverse merger transaction.	CI
25-08-21	Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. Enters into Purchase Agreement the Proceeds Will Be Used to Advance the Second Phase 3 Clinical Trial for the Development of Sp-102	CI
25-08-15	Denali Capital Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-13	Scilex announces S-4 effectiveness for Denali-Semnur merger proposal	RE
25-05-16	Denali Capital Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-14	Denali Capital Acquisition Corp.(OTCPK:DNQA.F) dropped from NASDAQ Composite Index	CI
25-04-14	Denali Capital Shareholders Approve Extension For Business Combination Deadline	RE
25-04-14	Denali Capital Gets Shareholder Nod to Extend Merger Deadline	MT
25-04-02	Denali Capital Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-01	Denali Capital Acquisition Corp. Auditor Raises 'Going Concern' Doubt	CI
25-03-12	Denali Capital Acquisition Pushes Merger Deadline With Extra Funding	MT
25-03-11	Denali Capital Acquisition Announces Extension Of Deadline To Complete Business Combination	RE

25-09-23	Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination	AQ
25-08-13	Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex	AQ
25-06-11	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination	GL
25-05-09	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination	GL
25-04-14	Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination	GL

1 year	0.65	12.05
3 years	0.65	14.1
5 years	0.65	14.1
10 years	0.65	14.1

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/30/24	Denali Capital Global Investments LLC	Sell	Company	500,000	24.2424%
8/30/24	Denali Capital Global Investments LLC	Sell	Company	500,000	24.2424%
5/21/22	Denali Capital Global Investments LLC	Issuer sale	Company	93,750	5.0000%

DENI CAPPAR Stock

Stocks

DNQAF

KYG6256B1068

Valuation: DENI CAPPAR

Chart: DENI CAPPAR

Latest news : DENI CAPPAR

Press Releases: DENI CAPPAR

Quotes and Performance

Course Extremes

Latest insider transactions

Financials

Company Profile

Quotes

Income Statement and Estimates

	2023	2024
Net sales	-	-
Net income	633K 556K 517K 474K 891K 60.91M 905K 6.14M 2.4M 29.95M 2.37M 2.32M 104M	-167K -147K -137K -125K -236K -16.11M -239K -1.62M -634K -7.92M -628K -615K -27.39M
Net Debt	1.61M 1.42M 1.32M 1.21M 2.27M 155M 2.31M 15.65M 6.11M 76.37M 6.06M 5.92M 264M	2.76M 2.42M 2.25M 2.07M 3.88M 265M 3.94M 26.74M 10.45M 131M 10.35M 10.13M 451M

1 day	+4.62%
Current month	-94.36%
Current year	-94.36%